This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Head & Neck Cancer  • Dermatology  • Neoplasms of Head & Neck  • Immunology  • Alert me on articles by topic  Social Bookmarking   What's this?

Walter T. Lee, MD; Hidemasa Tamai, MD; Peter Cohen, MD; Aysenur Meric Teker, MD; Suyu Shu, PhD

Arch Otolaryngol Head Neck Surg. 2008;134(6):608-613.

Objective  To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC).

Design  Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2^K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse.

Subjects  Female C3H/HEN mice aged 8 to 12 weeks.

Interventions  Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 x 10⁶ per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment.

Main Outcome Measures  Tumor size and overall survival.

Results  Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models.

Conclusion  Immunotherapy with fused dendritic-tumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.

Author Affiliations: Center for Surgery Research (Drs Lee, Cohen, Teker, and Shu) and Head and Neck Institute (Drs Lee and Teker), Cleveland Clinic, Cleveland Ohio; and Surgery and Oncology of the Digestive System, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (Dr Tamai).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?